Chiesi signs $1.9B deal to acquire KalVista and its approved drug

Kyle LaHucik / endpoints - Chiesi is buying commercial biotech KalVista Pharmaceuticals for about $1.9 billion in an extension of the industry's vigorous spring shopping spree. The Italian pharma will pay $27 per share {$KALV} in cash to buy the ...

AI Summary: Chiesi Group agreed to buy KalVista for $1.9 billion to secure an approved therapy and expand its rare-disease footprint. The deal transfers marketed assets and R&D capacity, positioning Chiesi to scale rare-disease revenues and invest in next-wave therapeutics — essentially a big check for a bigger strategic play.

---

Warning: Undefined variable $thumbnail in /home3/thegood9/public_html/website_70aad9ea/cluster.php on line 61

Related Stories

---

Warning: Undefined variable $top_stories in /home3/thegood9/public_html/website_70aad9ea/cluster.php on line 128

Eli Lilly buys Centessa for $6.3B to enter sleep disorder market / 2 months

Biogen announces $5.6B acquisition of Apellis Pharma / 1 month

Gilead buys Ouro Medicines for about $1.68–1.7B to bolster autoimmune pipeline / 2 months

Novartis closes Avidity deal; Atrium Therapeutics spinout launches / 2 months

Neurocrine buys Soleno Therapeutics for $2.9B to gain Prader‑Willi drug / 7 wks

Avalyn upsizes IPO to raise cash for lung drug trials / 29 days

BioMarin Phase 3 failure dims hopes for rare‑disease therapy / 8 days